Home » Topics » BioWorld Science

BioWorld Science
RSS

DoD funding supports Rigel's phase III trial of fostamatinib in hospitalized COVID-19 patients

Feb. 1, 2021

Interim data from phase II study of N-803 plus checkpoint inhibitors in NSCLC

Feb. 1, 2021

INCB-001158 plus chemotherapy shows promise for treating advanced biliary tract cancer

Feb. 1, 2021

PERK inhibition promising for pulmonary arterial hypertension

Feb. 1, 2021

IGV-001 shows safety and efficacy in phase Ib study in newly diagnosed glioblastoma

Feb. 1, 2021

Medshine Discovery patents multitargeted inhibitors of IRAK-4 and BTK

Feb. 1, 2021

New MAP4K1 inhibitors discovered at Guangdong Newopp Biopharmaceuticals

Feb. 1, 2021

Nanjing Zhengxiang Pharmaceuticals divulges new MAP4K1 inhibitors

Feb. 1, 2021

Innovation to initiate phase II study of Brilacidin for the treatment of COVID-19

Feb. 1, 2021

Bukwang concludes enrollment of clinical trial of clevudine as treatment of COVID-19

Feb. 1, 2021

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...